STAT

The gatekeeper: If you want to make it big in health care, it’ll help to get past Lisa Suennen first

Lisa Suennen is a gatekeeper for the next big ideas in health care. Don't try to sell her on hype.

MILL VALLEY, Calif. — Lisa Suennen is a unicorn collector.

Here in the seaside office where she takes pitches from health care entrepreneurs, she displays a children’s book titled “If I Were a Unicorn.” It sits behind a headband with a gleaming golden horn and a long trailing mane of hair in all the colors of the rainbow. She also sometimes wears a pair of 4-inch designer stilettos patterned with unicorns.

Why? Silicon Valley’s starry-eyed metaphor for privately held startups valued over $1 billion, Suennen explained, “is a silly construct — and so I have silly things.”

In an industry in which hype can often overtake reality, Suennen (pronounced SOON-en) is quicker than most to call out silliness. She has a reputation as an irreverent straight-talker and, as the lead health care investor for General Electric’s corporate venture arm, she has a knack for deflating doomed business models and bad ideas for improving health care.

She also doesn’t hesitate to make light of those who take themselves overly seriously.

In a recent interview in her office, her expression turned conspiratorial as she described the iconic five-star Rosewood Sand Hill hotel in Menlo Park, Calif., where she’d attended a business dinner the previous evening. “It is straight out of Central

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks